Vericel Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Vericel Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $276.26M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $237.22M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $197.52M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $164.37M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $156.18M | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | $45.23M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $32.26M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $20.01M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $26.68M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $39.39M | Feb 24, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $276.26M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $237.22M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $197.52M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $163.70M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $153.08M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $121.97M | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | $39.39M | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | $30.50M | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | $26.15M | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | $21.81M | Feb 25, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $23.35M | Mar 5, 2018 |
| FY2017 | Sep 30, 2017 | $14.26M | Mar 5, 2018 |
| FY2017 | Jun 30, 2017 | $16.95M | Mar 5, 2018 |
| FY2017 | Mar 31, 2017 | $9.36M | Mar 5, 2018 |
| FY2017 | Dec 31, 2016 | $16.52M | Mar 5, 2018 |
| FY2017 | Sep 30, 2016 | $10.93M | Mar 5, 2018 |
| FY2017 | Jun 30, 2016 | $12.82M | Mar 5, 2018 |
| FY2017 | Mar 31, 2016 | $14.11M | Mar 5, 2018 |
| FY2016 | Dec 31, 2015 | $15.42M | Mar 13, 2017 |
| FY2016 | Sep 30, 2015 | $11.31M | Mar 13, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $205.60M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $172.11M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $135.58M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $109.79M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $106.03M | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | $33.65M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $22.47M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $11.35M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $16.76M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $28.81M | Feb 24, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.52M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $10.36M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($3.18M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($16.71M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($7.47M) | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | $12.22M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $3.62M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | ($8.27M) | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | ($4.71M) | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $9.50M | Feb 24, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.04M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.52M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($6.46M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($17.06M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($7.85M) | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | $12.29M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $3.52M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | ($8.36M) | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | ($5.08M) | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $9.21M | Feb 24, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.56M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $24.80M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $21.04M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $19.94M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $16.29M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $13.02M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $30.39M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $13.60M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $12.94M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $15.30M | Feb 26, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $166.99M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $142.79M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $121.00M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $106.90M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $97.59M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $68.84M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $61.14M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $49.01M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $35.61M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $27.39M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.91M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $58.16M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $35.31M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $17.69M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $29.04M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $17.57M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | ($7.18M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($412.0K) | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | ($13.18M) | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | ($19.89M) | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.16M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $63.97M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $20.01M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $7.60M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $7.92M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $2.63M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $2.62M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $2.68M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $1.51M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $1.42M | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $487.97M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $432.72M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $353.66M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $273.00M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $243.71M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $205.61M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $153.24M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $118.69M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $54.58M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $48.60M | Mar 5, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $133.33M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $140.76M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $127.71M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $80.73M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $73.24M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $71.35M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $42.15M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $16.46M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $32.04M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $23.89M | Mar 5, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $354.64M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $291.97M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $225.95M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $192.27M | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $170.46M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $134.26M | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | $111.09M | Feb 23, 2023 |
| FY2021 | Dec 31, 2018 | $102.23M | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | $22.54M | Feb 24, 2021 |
| FY2019 | Dec 31, 2016 | $24.71M | Feb 25, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($376.30M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($392.82M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($403.18M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($400.00M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($383.29M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($375.82M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($378.68M) | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | ($369.01M) | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | ($360.88M) | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | ($343.59M) | Mar 5, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $100.09M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $74.52M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $69.09M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $51.07M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $68.33M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $33.62M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $26.89M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $18.29M | Feb 24, 2021 |
| FY2013 | Dec 31, 2013 | $8.06M | Mar 13, 2014 |
| FY2013 | Dec 31, 2012 | $13.64M | Mar 13, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 24, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 24, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 50.62M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 49.63M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 47.83M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 47.25M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 46.88M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 45.80M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 44.86M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 43.58M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | 35.86M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 31.60M | Mar 5, 2018 |